Analysts expect Catalent Inc (NYSE:CTLT) to post $0.40 earnings per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Catalent’s earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.31. Catalent posted earnings per share of $0.38 during the same quarter last year, which indicates a positive year-over-year growth rate of 5.3%. The business is scheduled to announce its next earnings results on Thursday, May 3rd.
On average, analysts expect that Catalent will report full-year earnings of $1.64 per share for the current financial year, with EPS estimates ranging from $1.50 to $1.73. For the next financial year, analysts forecast that the company will post earnings of $1.86 per share, with EPS estimates ranging from $1.58 to $1.97. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. During the same period in the previous year, the company posted $0.27 EPS. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year.
Shares of Catalent (CTLT) opened at $41.58 on Thursday. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. Catalent has a one year low of $27.48 and a one year high of $47.87. The stock has a market capitalization of $5,415.41, a price-to-earnings ratio of 72.95, a P/E/G ratio of 2.33 and a beta of 1.47.
In other news, insider John R. Chiminski sold 181,458 shares of the stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction dated Tuesday, November 21st. The shares were purchased at an average price of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. 361 Capital LLC increased its position in shares of Catalent by 18.6% during the 3rd quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock valued at $2,795,000 after purchasing an additional 10,974 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Catalent by 25.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock valued at $41,773,000 after purchasing an additional 210,296 shares during the last quarter. Sei Investments Co. increased its position in shares of Catalent by 119.1% during the 3rd quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock valued at $3,761,000 after purchasing an additional 51,212 shares during the last quarter. Stevens Capital Management LP bought a new position in shares of Catalent during the 3rd quarter valued at about $2,475,000. Finally, Emerald Mutual Fund Advisers Trust bought a new position in shares of Catalent during the 3rd quarter valued at about $18,420,000. Hedge funds and other institutional investors own 99.82% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.